AP768

AP768 is a potent, selective, small molecule antagonist of the CRTH2 (chemoattractant receptor-homologous molecule expressed on Th2 cells) receptor, also known as the Prostaglandin D2 receptor 2 (DP2). Originally developed by Bayer AG and subsequently by Actimis Pharmaceuticals, the compound was designed for the once-daily oral treatment of asthma and other respiratory and immune-mediated diseases. By blocking the CRTH2 receptor, AP768 inhibits the activation and chemotaxis of Th2 cells, eosinophils, and basophils, aiming to modify the underlying disease course of asthma rather than just providing symptom relief. Boehringer Ingelheim entered into a conditional acquisition agreement for Actimis Pharmaceuticals based on the clinical progress of AP768, though development appears to have been discontinued prior to reaching Phase III.